Literature DB >> 10896228

The RsaI polymorphism in the alpha-fibrinogen gene and response of plasma fibrinogen to physical training--a controlled randomised clinical trial in men.

R Rauramaa1, S B Väisänen, R Kuhanen, I Penttilä, C Bouchard.   

Abstract

We have previously reported cross-sectional data on an interaction effect between physical activity and alpha-fibrinogen RsaI polymorphism on fibrinogen in postmenopausal women. In the present controlled randomised study, we investigated the role of the RsaI polymorphism in determining the response of fibrinogen to long-term regular exercise. Middle-aged men (n = 140), randomly selected from the population registry, were randomised into an exercise or a reference group for a 3-year low intensity exercise intervention. Complete data were available in 125 men. The RsaI restriction enzyme detects threonine (Thr) to alanine change in the fibrinogen alpha codon 312. Anaerobic ventilatory threshold increased by 4%, but decreased by 2% in the exercise and reference groups, respectively. Mean fibrinogen did not decrease in either study group. However, in the exercise group, individual changes in anaerobic threshold explained 48% of the variance in fibrinogen changes in the Thr homozygotes. Our data offer a new aspect of beneficial effects of regular physical exercise on risk factors for coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10896228

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  3 in total

1.  Exercise, lipids, and lipoproteins in older adults: a meta-analysis.

Authors:  George A Kelley; Kristi S Kelley; Zung V Tran
Journal:  Prev Cardiol       Date:  2005

2.  Aerobic exercise and lipids and lipoproteins in men: a meta-analysis of randomized controlled trials.

Authors:  George A Kelley; Kristi S Kelley
Journal:  J Mens Health Gend       Date:  2006

Review 3.  Exercise-induced changes in coagulation and fibrinolysis in healthy populations and patients with cardiovascular disease.

Authors:  Christopher J Womack; Paul R Nagelkirk; Adam M Coughlin
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.